CD3ζ-based chimeric antigen receptors mediate T cell activation viacis- andtrans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Suppression of Human Glioma Xenografts with Second-Generation IL13R-Specific Chimeric Antigen Receptor-Modified T Cells

(2012) S. Kong et al.   CLINICAL CANCER RESEARCH

SPICE: Exploration and analysis of post-cytometric complex multivariate datasets

(2011) Mario Roederer et al.   CYTOMETRY PART A

Ligation of the CD2 co-stimulatory receptor enhances IL-2 production from first-generation chimeric antigen receptor T cells

(2011) E J Cheadle et al.   GENE THERAPY

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Building Better Chimeric Antigen Receptors for Adoptive T Cell Therapy

(2010) John S. Bridgeman et al.   CURRENT GENE THERAPY

T cell activation upon exposure to patient-derived tumor tissue: A functional assay to select patients for adoptive T cell therapy

(2010) Caroline Schroten et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Cutting Edge: Mechanical Forces Acting on T Cells Immobilized via the TCR Complex Can Trigger TCR Signaling

(2010) Y. C. Li et al.   JOURNAL OF IMMUNOLOGY

The Optimal Antigen Response of Chimeric Antigen Receptors Harboring the CD3  Transmembrane Domain Is Dependent upon Incorporation of the Receptor into the Endogenous TCR/CD3 Complex

(2010) J. S. Bridgeman et al.   JOURNAL OF IMMUNOLOGY

Development of a flow cytometric co-immunoprecipitation technique for the study of multiple protein-protein interactions and its application to T-cell receptor analysis

(2009) John S. Bridgeman et al.   CYTOMETRY PART A

Eradication of Established B-cell Lymphoma by CD19-specific Murine T Cells is Dependent on Host Lymphopenic Environment and Can be Mediated by CD4+ and CD8+ T Cells

(2009) Eleanor J. Cheadle et al.   JOURNAL OF IMMUNOTHERAPY

The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma

(2008) Eleanor J Cheadle et al.   BRITISH JOURNAL OF HAEMATOLOGY